Pharmacyte Biotech Cash Flow - Annual (OTCMKTS:PMCB)

Add to My Stocks
$0.05 $0 (0%) PMCB stock closing price Sep 20, 2018 (Closing)

The Pharmacyte Biotech cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Pharmacyte Biotech profits one has to check the income statement and for Pharmacyte Biotech debt one has to check the balance sheet. Pharmacyte Biotech cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Pharmacyte Biotech had cash and cash equivalents of $1.92M at the beginning of the year and $3.46M at year end for 2017. PMCB decrease in investments stood at a value of $- for the latest year 2017.

View details of Pharmacyte Biotech cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is May - Apr201720162015201420132012201120102009
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow-----0.01M----
Net Increase (Decrease) in Assets Liabilities-0.02M-0.87M1.74M-0.49M-----
Cash From (used in) Discontinued Operations---------
Other Adjustments Net1.12M2.59M4.55M26.18M-1.38M-3.97M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment---------
Acquisition Disposition of Subsidiaires----0.05M-0.64M-0.87M---
Increase (Decrease) in Investments---------
Other Cash Inflow (Outflow) from Investment Activities----3.5M-----
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares4.88M3.56M3.78M8.51M1.14M----
Issuance (Repayment) of Debt Securities---0.14M--1.06M---
Increase (Decrease) in Bank & Other Borrowings--------0.2M-
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities---------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year1.92M2.69M3.61M------
Cash & Equivalents at Year End3.46M1.92M2.69M3.61M-----
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Pharmacyte Biotech stock comparison chart provides an easy way to compare the stock price with peers along with details of Pharmacyte Biotech stock price history.
The statement of cash flows can be categorized into three main sections:

  • Pharmacyte Biotech saw a positive change in Net Change in Cash and Cash Equivalents of $1.54M in 2017. Apart from the Pharmacyte Biotech stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: Pharmacyte Biotech reported a negative operating cash flow of $-3.33M for 2017 and has seen an increase from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $- for PMCB in last 2017 report.
  • Cash flow from financing activities shows the flow of cash between Pharmacyte Biotech and its owners and creditors and was $4.88M for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Pharmacyte Biotech Cash Flow

FCF margin